St. Jude Medical CEO: Medtronic, Inc.'s Failure Doesn't Dampen Our Spirits

St. Jude Medical president & CEO Dan Starks says that rival Medtronic's failed renal denervation study is not reason to stop pursuing the technology in treatment of hypertension. "The fact that we had and that there have been favorable early clinical results in numerous other experiences is still valid," Starks said. "There is open surgical data dating back several decades that was favorable to the impact of surgical renal denervation to treat hypertension."

Help employers find you! Check out all the jobs and post your resume.